0001183740-19-000232.txt : 20191107 0001183740-19-000232.hdr.sgml : 20191107 20191107142627 ACCESSION NUMBER: 0001183740-19-000232 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 EFFECTIVENESS DATE: 20191107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LexaGene Holdings Inc. CENTRAL INDEX KEY: 0001450416 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-352859 FILM NUMBER: 191199819 BUSINESS ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: 800-215-1824 MAIL ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP. DATE OF NAME CHANGE: 20100729 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP DATE OF NAME CHANGE: 20081119 D 1 primary_doc.xml X0708 D LIVE 0001450416 LexaGene Holdings Inc. 500 CUMMINGS CTR., SUITE 4550 BEVERLY MA MASSACHUSETTS 01915 800-215-1824 BRITISH COLUMBIA, CANADA STONESHIELD CAPITAL CORP. STONESHIELD CAPITAL CORP Corporation true Daryl Rebeck 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Director John (Jack) F Regan 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Director Thomas Richard Slezak 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Manohar R Furtado 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Joseph M Caruso 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Jeffrey M Mitchell 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Biotechnology Decline to Disclose 06b false 2019-10-29 true true true true false 0 2439446 998828 1440618 Total Offering Amount equals the price of units(2516280 @ C$0.52), plus the aggregate exercise price of the underlying warrants(2516280 @ C$0.75), converted at US$1:C$1.31. There is no assurance that the warrants, expiring 29 Oct 2022, will be exercised. false 19 0 0 0 false LexaGene Holdings Inc. /s/ Jeffrey Mitchell Jeffrey Mitchell CFO 2019-11-06